Navigation Links
European Multidisciplinary Conference in Thoracic Oncology -- press program
Date:2/23/2011

The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at media@esmo.org. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.

  1. Quick, easy test identifies aggressive type of lung cancer in never-smokers (embargo: 25 February 2011, 8:00 CET)
    Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
    Author: Ping Yang, US

  2. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer (embargo: 25 February 2011, 8:00 CET)
    Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
    Author: Rafael Rosell, Spain

  3. Bone drug zoledronic acid may help prevent spread of early lung cancer (embargo: 25 February 2011, 8:00 CET)
    Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
    Author: Michela Quirino, italy

  4. Radio-guided surgery, a safe and simple way to remove potentially cancerous nodules in the lung (embargo: 26 February 2011, 8:00 CET)
    Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
    Author: Luca Bertolaccini, Italy

  5. Phase III trial: erlotinib as effective as chemo, with fewer side-effects, in patients whose disease progressed after first-line treatment (embargo: 26 February 2011, 8:00 CET)
    Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
    Author: Tudor Ciuleanu, Romania


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. IOF calls on European citizens to stand tall and speak out for their bones
2. IronKey Opens New European Office
3. European researchers harness unique properties of boron to develop new drugs and diagnostics
4. Vidaza receives positve opinion from European CHMP
5. The MDS foundation supports vidazas recommendation for European approval
6. European biodiversity and ecosystem scientists merge and gear up for long-term research
7. Overfishing threatens European bluefin tuna
8. European ancestry increases breast cancer risk among Latinas
9. IRB Barcelona to coordinate two European projects on biomedicine
10. Key to future medical breakthroughs is systems biology, say leading European scientists
11. Global warming linked to European viral epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: